Literature DB >> 16181242

Hypertension in acromegaly and in the normal population: prevalence and determinants.

Giovanni Vitale1, Rosario Pivonello, Renata S Auriemma, Ermelinda Guerra, Francesco Milone, Silvia Savastano, Gaetano Lombardi, Annamaria Colao.   

Abstract

BACKGROUND: The GH/IGF-I axis has a relevant role to play in the cardiovascular system but its implication in the pathogenesis of hypertension in the normal population and in acromegaly is not yet clear. PATIENTS AND MEASUREMENTS: The aim of this retrospective and controlled study was to evaluate the prevalence and determinants of hypertension in 200 patients with acromegaly and 200 nonacromegalic subjects, matched for sex, age, body mass index (BMI) and smoking habits.
RESULTS: Hypertension was found in 46% of patients and in 25% of controls (P < 0.0001), without any difference between men and women. Family history of hypertension occurred in 30% of hypertensive acromegalic patients and in 62% of hypertensive controls (P < 0.0001). In both groups, hypertensive subjects were older than normotensive subjects. Systolic (SBP) and diastolic blood pressures (DBP) in hypertensive acromegalic patients were lower and higher, respectively, than in hypertensive controls. The risk of hypertension increased with age and was higher in the patients than in the controls [hazard ratio (HR) 1.9; P = 0.0002]. Independent predictors of SBP were age and glucose in the acromegalic population, and BMI, age and glucose levels in the controls. Independent predictors of DBP were age and glucose in the patients, and BMI, age and IGF-I in the controls.
CONCLUSIONS: In acromegaly, hypertension is more frequent than in the general population, involves predominantly DBP, and occurs earlier, is not related to gender, and is less frequently related to family history of hypertension and IGF-I levels. IGF-I may have a protective role for DBP in the general population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181242     DOI: 10.1111/j.1365-2265.2005.02370.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

Review 1.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

2.  Atrial conduction times and left atrium mechanical functions in patients with active acromegaly.

Authors:  A Ilter; A Kırış; Ş Kaplan; M Kutlu; M Şahin; C Erem; N Civan; F Kangül
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

Review 3.  [Malign and refractory hypertension].

Authors:  Georg Schaller; Michael Wolzt
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 4.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

5.  Left ventricular synchronicity is impaired in patients with active acromegaly.

Authors:  Abdulkadir Kırış; Cihangir Erem; Oğuzhan Ekrem Turan; Nadim Civan; Gülhanım Kırış; Irfan Nuhoğlu; Abdulselam Ilter; Halil Onder Ersöz; Merih Kutlu
Journal:  Endocrine       Date:  2012-12-20       Impact factor: 3.633

6.  Elevated systolic blood pressure in male GH transgenic mice is age dependent.

Authors:  Adam Jara; Chance M Benner; Don Sim; Xingbo Liu; Edward O List; Lara A Householder; Darlene E Berryman; John J Kopchick
Journal:  Endocrinology       Date:  2013-01-01       Impact factor: 4.736

7.  Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.

Authors:  Brian J Potter; Catherine Beauregard; Omar Serri
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

8.  Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.

Authors:  Karen K Miller; Tamara Wexler; Pouneh Fazeli; Lindsay Gunnell; Gwenda J Graham; Catherine Beauregard; Linda Hemphill; Lisa Nachtigall; Jay Loeffler; Brooke Swearingen; Beverly M K Biller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

9.  Assessment of cardiac autonomic functions by heart rate recovery, heart rate variability and QT dynamicity parameters in patients with acromegaly.

Authors:  Muhammet Dural; Giray Kabakcı; Neşe Cınar; Tomris Erbaş; Uğur Canpolat; Kadri Murat Gürses; Lale Tokgözoğlu; Ali Oto; Ergün Barış Kaya; Hikmet Yorgun; Levent Sahiner; Selçuk Dağdelen; Kudret Aytemir
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

10.  Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.

Authors:  Cihangir Erem; Irfan Nuhoglu; Mustafa Kocak; Mustafa Yilmaz; Safiye Tuba Sipahi; Ozge Ucuncu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.